Medtronic Hits 10-Year Revenue High, Advances MiniMed Diabetes Unit IPO

Key Facts

1Medtronic reported $36.4 billion in revenue for FY26, marking its strongest top-line performance in a decade.

2The company returned $4.2 billion to shareholders through dividends and share repurchases.

3Medtronic is advancing strategic initiatives including the IPO of its Diabetes business, MiniMed.

In a move reflecting robust financial performance within the medical technology sector, Medtronic has delivered its strongest top-line results in a decade for fiscal year 2026. According to reports, the company generated $36.4 billion in revenue, supported by 5.8% organic growth, highlighting the success of its current expansion strategies. Furthermore, the company bolstered shareholder confidence by returning $4.2 billion through dividends and share repurchases.

These strong results coincide with Medtronic's preparations for its Annual General Meeting on October 15, where shareholders will vote on proposals including director elections and share issuance authorizations. A key strategic focus remains the 'MiniMed' diabetes business unit, as the company advances plans for its initial public offering (IPO) as part of a broader portfolio restructuring aimed at improving profit margins.

In the markets, MDT stock stood at $91.27 at the close of August 14, 2026, having traded within a daily range of $90.41 to $91.99. With no immediate healthcare-specific catalysts in the upcoming economic calendar, traders will closely monitor further updates regarding the MiniMed IPO timeline, which could serve as a significant driver for the stock's valuation in the coming period.

Sources:

Stock Titan